Should My Patient Receive a WATCHMAN Device?
An 80-year-old female patient with known atrial fibrillation (AF) and a CHA2DS2-VASc score of 4 is admitted to the medical intensive care unit with a life-threatening gastrointestinal (GI) bleed. No clear GI source of blood loss is found. You are asked to render an opinion regarding restarting anticoagulation.
Regarding the WATCHMAN (Boston Scientific; Marlborough, MA) device now being used widely in the treatment of patients with AF who may no longer be suitable for long-term anticoagulation, which of the following is true?